Vivo Capital, LLC Q2 2017 Filing
Filed August 2, 2017
Portfolio Value
$397.1B
Holdings
26
Report Date
Q2 2017
Filing Type
13F-HR
All Holdings (26 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | ACRSAclaris therapeutics | 2,858,569 | $77.5B | 19.52% | |
| 2 | —Biohaven Pharmaceutical Holding Company Ltd | 1,976,818 | $49.4B | 12.45% | |
| 3 | ASNDAscendis Pharma | 1,766,832 | $49.0B | 12.35% | |
| 4 | —Nabriva Therapeutics AG | 4,021,559 | $42.1B | 10.61% | |
| 5 | CDXSCodexis, Inc. | 5,294,825 | $28.9B | 7.27% | |
| 6 | SELBUSDSelecta Biosciences, Inc. | 1,119,189 | $22.2B | 5.60% | |
| 7 | —Strongbridge Biopharma plc | 3,000,000 | $21.4B | 5.40% | |
| 8 | —Aimmune Therapeutics, Inc. | 776,813 | $16.0B | 4.02% | |
| 9 | CLDNEUREiger BioPharmaceuticals | 1,787,091 | $14.1B | 3.56% | |
| 10 | —Advanced Accelerator Applications S.A. | 358,786 | $14.0B | 3.53% | |
| 11 | VRNAVerona Pharma Plc | 704,225 | $8.2B | 2.07% | |
| 12 | —Capnia, Inc. | 14,695,264 | $7.4B | 1.85% | |
| 13 | —BioPharmX Corporation | 14,096,338 | $6.8B | 1.70% | |
| 14 | AUPHAurinia Pharmaceuticals Inc. | 1,013,149 | $6.2B | 1.56% | |
| 15 | —Agile Therapeutics, Inc. | 1,513,975 | $5.7B | 1.43% | |
| 16 | —Trevena, Inc. | 1,728,000 | $4.0B | 1.00% | |
| 17 | —Foamix Pharmaceuticals Ltd. | 855,000 | $4.0B | 1.00% | |
| 18 | DVAXDynavax Technologies Corporation | 359,827 | $3.5B | 0.87% | |
| 19 | RGNXRegenxbio Inc. | 164,403 | $3.2B | 0.82% | |
| 20 | —Sierra Oncology, Inc. | 2,438,270 | $2.9B | 0.72% | |
| 21 | —Akari Therapeutics Plc | 527,842 | $2.4B | 0.61% | |
| 22 | CRSPCRISPR Therapeutics AG | 148,878 | $2.4B | 0.60% | |
| 23 | —KalVista Pharmaceuticals, Inc. | 300,325 | $2.2B | 0.56% | |
| 24 | RVNCEURReVance Therapeutics, Inc. | 77,373 | $2.0B | 0.51% | |
| 25 | —Sunesis Pharmaceuticals, Inc. | 500,000 | $1.4B | 0.34% | |
| 26 | —Capnia, Inc. | 943,858 | $159.0M | 0.04% |